Home

2010 BEN AND CATHERINE IVY FOUNDATION RESEARCH AWARDS SUMMIT AGENDA

2010 BEN AND CATHERINE IVY FOUNDATION RESEARCH AWARDS SUMMIT:
ADVANCING PATIENT-FOCUSED RESEARCH
January 15th, 2010

MEETING GOALS

  1. REVIEW RESEARCH PROJECT RESULTS AND THEIR IMPLICATIONS;
  2. IDENTIFY WAYS THE RESEARCH PROJECTS CAN BE STRENGTHENED TO MAXIMIZE IMPACT; 
  3. IDENTIFY AREAS WHERE PIS CAN COLLABORATE AND/OR SHARE RESOURCES.

AGENDA
8:00-8:15AM  WELCOME AND OPENING: Advancing a Patient-Focused Treatment Paradigm.    
Speakers: Catherine Ivy and Rob Tufel, The Ben & Catherine Ivy Foundation.                       

8:15-9:30AM  SESSION I: “Is Therapy Working?” – Disease Monitoring and Detection through Noninvasive Biomarkers.
Session Chair: David Parkinson, MD, Nodality; Ivy 2008 Scientific Reviewer Network.

  • 8:15-8:35AM
    Development and Implementation of Novel Molecular Diagnostic Tools to Guide Combination Therapy for Malignant Glioma Patients.
    Speaker: Jim Heath, MD, CalTech.
  • 8:40-9:00AM
    Targeting Glioblastoma through Tumor Endothelial Marker-1 (TEM1).
    Speaker: George Coukos, MD, PhD, University of Pennsylvania.
  • 9:05-9:25AM
    18    F FPPRGD2 PET/CT, 18F FDG PET/CT and MRI Evaluation of Response to Anti-Angiogenesis Therapy in Recurrent Glioblastoma Multiforme.”
    Speaker: Andrei Iagaru, MD, Stanford University.

9:30-9:55AM  PANEL DISCUSSION WITH SESSION I SPEAKERS: Meeting Project Challenges.
Moderator: David Parkinson, MD.                            

9:55-10:15AM  eBREAK

10:15-11:30AM  SESSION II: “What Treatments Are Available And What Is the Best Option For Me?” – Preclinical and Clinical Therapeutics Testing.
Session Chair: Heidi Phillips, PhD, Genentech; Ivy 2008 Scientific Reviewer Network.

  • 10:15-10:35AM
    p75NTR is a rational drug target for malignant glioma.
    Speakers: Peter Forsyth, MD, University of Calgary.
  • 10:40-11:00AM
    The Ivy Genomics-Based Medicine Project (Ivy G.B.M. Project).
    Speaker: Mike Berens, PhD, Translational Genomics Research Institute.
  • 11:05-11:25AM
    Ivy Early Phase Clinical Trials Consortium.
    Speaker: Mike Prados, MD, University of California, San Francisco.

11:30-11:55AM  PANEL DISCUSSION WITH SESSION II SPEAKERS: Meeting The Challenges.
Moderator: Heidi Phillips, PhD.

11:55AM-1:15PM  LUNCH

1:15-2:05PM  SESSION III: “What Treatments Are Available And What Is the Best Option For Me?” – Strategies for Identifying Combination Therapies.
Session Chair: Cathy Nutt, PhD, Harvard Medical School / Massachusetts General Hospital; Ivy 2008 Scientific Reviewer Network.

  • 1:15-1:35PM
    Systematic Functional Interrogation of the GBM Genome for Curative Combination Therapy.
    Speaker: Giulio Draetta, MD, PhD, Dana-Farber Cancer Institute.
  • 1:40-2:00PM
    Using Genomic Signatures to Predict Combinational Therapy for GBM.
    Speaker: Joseph Nevins, MD, Duke University.
  • 2:05-2:30PM  PANEL DISCUSSION WITH SESSION III SPEAKERS: Meeting The Challenges.
    Moderator: Cathy Nutt, PhD.

2:30-2:45PM  eBREAK

2:45-3:30PM  SESSION IV: What Questions in Tumor Biology Are Key for Realizing “Tomorrow’s” Scenario? – Views from the Patient-Focused Research Perspective.
Session Chair: Richard Gilbertson, MD, PhD, St. Jude Children’s Hospital; Ivy 2008 and 2009 Scientific Reviewer Network.

  • 2:45-3:05PM
    The Ivy GBM Atlas Project (Ivy GAP).
    Speaker: Greg Foltz, MD, Swedish Medical Center, and Ralph Puchalski, PhD, The Allen Institute for Brain Science.
  • 3:10-3:30PM
    Glioma Cancer Stem Cells and Tumor-Derived Mesenchymal Stem Cells: Role and Crosstalk in Human Gliomas.
    Speaker: Fred Lang, MD, MD Anderson Cancer Center.

3:30-3:55PM  PANEL DISCUSSION WITH SESSION IV SPEAKERS: Meeting The Challenges.
Moderator: Richard Gilbertson, MD, PhD. 

3:55-4:30PM  BREAK-OUT SESSION: Leveraging Ivy-Funded Projects: Crosstalk, Critique, and Collaboration.
Session Chair: Joanne Salcido, PhD.
Tasks:
#1. Identify Action Items to maximize project performance and impact.
#2. Identify Opportunities for Collaboration/Cooperation (internally or externally) to leverage Ivy funding or maximize project performance.                          

4:30-5:00PM  REPORTS FROM BREAK-OUT GROUPS
Session Chair: Joanne Salcido, PhD
4:30-5:00 Reports by PIs on Break-Out session discussion.

5:00-5:15PM  “TOP 10” LIST – What are the Latest, Most Cutting-Edge Topics in Cancer Research?
Session Chair: Rob Tufel

5:15PM  Closing.